

Tetrahedron Letters 39 (1998) 6659-6662

An Efficient Synthesis of Protected 2-Deoxy-Streptamine and Analogues

Emerson T. da Silva, Mireille Le Hyaric, Antônio S. Machado and Mauro V de Almeida Departamento de Química, I.C.E., U F.J.F, 36036-330, Juiz de Fora, MG, Brazil Fax (032) 229-3314; e-mail mvieira@quimica.ufjf.br

Received 6 June 1998; revised 2 July 1998; accepted 6 July 1998


Abstract. Protected 2-deoxy-streptamine 13 and a variety of analogues 9, 10, 12, and 14 were synthesized, starting with the intermediate 2L-2,3,5/3-2,3,4-tri-Q-benzyl-1-syn-Q-oximino-2,3,4,5-cyclohexanetetrol 2, derived from D-glucose. © 1998 Elsevier Science Ltd. All rights reserved.

Since the discovery of the first aminoglycoside antibiotic, streptomycin,¹ in 1944 by Waksman, numerous aminoglycosides have been described The most important and clinically useful antibiotics such as neomycin, kanamycin, gentamycin and sisomycin contain 2-deoxy-streptamine 1 (Scheme 1) as the aminocyclitol subunit.² Despite intensive research interest in this area, only streptamine, 2-deoxy-streptamine and 2,5-dideoxy-streptamine are readily available. However, 2-deoxy-streptamine and 2,5-dideoxy-streptamine are not suitable for total chemical synthesis. They are *meso* compounds, and in order to avoid formation of complex diastereomeric mixtures on glycosylation, properly protected derivatives must be prepared in enantiomerically pure forms.

In this communication we wish to report the synthesis of protected 2-deoxy-streptamine 13 and the analogues 9, 10, 12, and 14.

The oxime 2 was elaborated from D-glucose *via* carbohydrate-inosose Ferrier rearrangement as previously described.^{3,4} The reduction of 2 with LiAlH₄ into the corresponding amine as described in the literature⁴ was unsuccessful. Speculating that the low reactivity of the oxime 2 towards LiAlH₄ reduction could be overcome through the protection of oximino group, compound 2 was treated with benzyl chloride in the presence of NaH in DMF. This reaction afforded regioselectively the derivative 3 {mp 82-84°C; $[\alpha]_D^{20}$ -16 (c=1.0; CHCl₃)(in 91% yield (Scheme 1). The *sym* configuration of 2 and 3 was determined from the ¹H and ¹³C NMR spectrum and by comparison with data from the literature.⁵ The reduction of 3 with LiAlH₄ gave a mixture of the epimeric amines 4 and 5 along with the benzylhydroxylamine 6⁶ in 90% yield (proportion 1.9.1). The compound 6 could be quantitatively deprotected to the amine 5 using NaBH₄ and NiCl₂ in methanol.⁷


Acetylation of 4 and 5 with acetic anhydride in methanol led to the N-acylated amines 7 {oil, $[\alpha]_D^{20}$ - 5; (c=2.7; CH₂Cl₂)} and 8 {mp 194-196°C; $[\alpha]_D^{20}$ +36 (c=1.1; CHCl₃)} in 90% yield. Substitution of the hydroxyl groups of 7 and 8 was performed using DAST in methylene chloride⁸, and the expected fluorinated analogues 9° and 10¹⁰ were both obtained in 70% yield



a) PhCH₂Cl, NaH, DMF, 0°C-100°C, 24h; b) LiAlH $_4$, THF, reflux, 12h; c) NaBH $_4$, NiCl₂, MeOH, -10°C, 4h; d) Ac₂O, MeOH, 0°C-r.t., 8h; c) DAST, CH ₂Cl₂, 0°C-r.t., 4h

Scheme 1

Compound 8 was converted to the mesylate 11^{11} {mp 175-177°C; $[\alpha]_D^{20}$ +75 (c=0.7; CHCl₃)} in 88% yield (Scheme 2) by treatment with methanesulfonyl choride in pyridine. Treatment of 11 with sodium azide in DMSO gave the compound 12^{12} in 88% yield. The latter was reduced by triphenylphosphine in THF giving the target compound 13 {dec.220-227°C; $[\alpha]_D^{20}$ +22 (c=2.3; CH₂Cl₂)} in 73% yield. Reaction of the mesylate 11 with potassium thioacetate in DMF afforded the desired compound 14^{13} in 34% yield. Optimization of this reaction is under investigation. The structures of all new compounds were unequivocally established by ¹H, cosy ¹H x ¹H and ¹³C NMR analysis.



a) MsCl, Pyr., 0°C- r.t., 12h; b) Na\\$, DMSO, 100°C, 48h; c) PPh3, THF/H2O, 0°C- r.t., 24h; d) KSAc, DMF, 100°C, 48h.

Scheme 2

Acknowledgement: We wish to thank Drs. S. D. Gero, J. Cleophax and R.H. Dodd for many helpful discussions. This research was supported by CNPq.

References and notes:

- (1) Waksman, S.A.; Schatx, A.; Bugie, E. Proc. Soc. Exp. Biol. Med. 1944, 55, 66.
- (2) Umezawa, H.; Kondo, S.; Kitasato, I. Drugs Exp. Clin. Res. 1984, 10, 63.
- (3) Ferrier, R.J. J. Chem. Soc. Perkin I 1979, 1455.
- (4) Semeria, D.; Philippe, M.; Delaumeny J.M.; Sepulchre, A.M.; Gero, S.D. Synthesis 1983, 710.
- (5) Filho, R.B., Antunes, O.A.C., Barnes, A. Química Nova 1988, 11, 488; Levy G.C.; Lichter R.L.; Nelson G L. Carbon 13 Nuclear Magnetic Resonance for Organic Chemists WILEY, 2nd. ed. 1980.
- 6) 6, caracterized as hydrochloride form, dec 172-174°C, [α]_D²⁰+33 (c=0.5; CHCl₃), MS (E.I):m/z=540 (M+H)⁻⁷
 ¹HNMR (400MHz; CDCl₃): δ 1.80 (m, 1H, H6a), 2.60 (m, 1H, H6e, J_{6a-6e}=12.7Hz), 3.35 (s, 1H, H4), 3.80 (s, 3H, H1, H2, H3), 4.05 (s, 1H, H-5), 4.50-4.90 (m, 6H, <u>CH2</u>Ph), 5.20 (dd, 2H, NO<u>CH2</u>Ph), 7.0-7.4 (m, 20H, Ph); ¹³CNMR (100,6MHz; CDCl₃): δ 28.02 (C6), 58.13 (C1), 65.41 (C4), 77.72 (C3), 82.53 and 82.71 (C2 and C4).
- (7) Ipaktschi, J. Chem. Ber. 1984, 117, 856.
- (8) Vieira de Almeida, M. Thesis, Orsay Paris XI 1993

- (9) 9, mp 73-75°C; $[\alpha]_D^{20}$ -6 (c=1 3, CH₂Cl₂) ¹HNMR (400 MHz; C₆D₆). δ 0.67 (m, 1H, H6a), 0.95 (s, 3H, CH₃), 1.85 (m, 1H, H6e), 2.62 (dd, 1H, H2, J₂₋₁=4.7 Hz, J₂₋₃=9 0 Hz), 2 77 (m, 1H, H4), 2.98 (t, 1H, H3, J₃₋₄=8.5 Hz), 3.90 (m, 1H, H1), 4 08 (m, 1H, H5, J_{5-F}=49 Hz, J₅₋₄=8.5 Hz, J_{5-6e}=3.5 Hz, J_{5-6a}=9.8 Hz), 3.63-4.26 (m, 6H, <u>CH₂Ph</u>), 5.20 (d, 1H, NH, J_{NH-1} = 6.9Hz), 6 44-6.73 (m, 15H, Ph); ¹³CNMR (100.6 MHz, CDCl₃): δ 23,28 (CH₃), 30.48 and 30.68 (C6), 44 23 and 44 36 (C1), 79.33 (C2), 80.03 and 80.13 (C3), 82.84 and 83.01 (C4), 90.35 and 92.11 (C5, J_{C5-F}=177 Hz), 170,74 (C=O)
- (10) **10**, mp 169-171°C; $[\alpha]_D^{20}$ +20 (c=0.4; CHCl₃) ¹HNMR (400 MHz; CDCl₃) δ 1 44 (m, 1H, H6a, J_{6a-6e}=12 Hz), 2.49 (m, 1H, H6e), 3.35 (dd, 1H, H2, J₂₋₃=8.6 Hz, J₂₋₁=10 Hz), 3.55 (t, 1H, H3, J₃₋₄=8.6 Hz), 3.60 (m, 1H, H4, J₄₋₅=8.5 Hz), 3.74 (m, 1H, H1), 4.60 (m, 1H, H5, J_{5-f}=49 Hz, J_{5-6a}=9.3 Hz), 4.60-4.92 (m, 7H, <u>CH2</u>Ph and NH), 7.25-7.40 (m, 15H, Ph), ¹³CNMR (100.6 MHz, CDCl₃) δ 23.34 (CH₃), 33.03 and 33.22 (C6), 47.05 and 47.21 (C1), 80.89 (C2), 82.81 and 82.93 (C3), 83.78 and 83.93 (C4), 90.51 and 92.30 (C5, J_{C5-F}=179 Hz), 169.88 (C=O).
- (11) **11**, mp 175-177°C; $[\alpha]_D^{20}$ +75 (c=0 7; CHCl₃)

¹HNMR (400MHz; CDCl₃): δ 1.72 (dt, 1H, H6a), 1.75 (s, 1H, <u>CH</u>₃CONH), 2.42 (dt, 1H, H6e, J_{6e-6a}=14.6 Hz, J_{6e-1}=J_{6e-5}=4.3 Hz), 3.07 (s, 3H, <u>CH</u>₃SO₃R), 3.53 (dd, 1H, H4, J₄₋₃=9.2 Hz, J₄₋₅=2.9 Hz), 3.57 (dd, 1H, H2, J₂₋₁=10 Hz, J₂₋₃=9.0 Hz), 3.85 (t, 1H, H3), 3.88 (m, 1H, H1), 4.60-4.93 (m, 6H, <u>CH</u>₂Ph), 5 13 (m, 1H, H5), 5.20 (d, 1H, NH), 7.27-7.38 (m, 15H, Ph); ¹³CNMR (100.6 MHz, CDCl₃): δ 23.47 (<u>CH</u>₃CO), 31.56 (C6), 39.33 (<u>CH</u>₃SO₃R), 48.39 (C1), 76.72, 80.20, 80.65 and 81 81 (C2, C3, C4 and C5), 170.26 (C=O).

- (12) **12**, mp 211-213°C; $[\alpha]_D^{20}$ +63 (c=0 9; CHCl₃) ¹HNMR (400MHz; C₆D₆): δ 0,58 (q, 1H, H6a, J_{6a-6e}=13Hz), 1.68 (dt, 1H, H6e, J_{6e-5}=J_{6e-1}=4.5 Hz), 1.86 (s, 3H, CH₃), 2.53 (m, 1H, H5, J₅₋₄=9.8 Hz), 2.73 (dd, 1H, H2, J₂₋₁=10.2 Hz, J₂₋₃=9.3 Hz), 2.88 (t, 1H, H4, J₄₋₃=9.4 Hz), 3.01 (t, 1H, H3), 3.46 (m, 1H, H1), 3.98 (d, 1H, NH, J_{NH-1}=7.2 Hz), 4.17-4.57 (m, 6H, <u>CH₂Ph</u>), 6.70-7.10 (m, 15H, Ph); ¹³CNMR (100.6 MHz; CDCl₃): δ 23.32 (CH₃), 33.10 (C6), 48.80 (C1), 60.77 (C5), 81.21 (C2), 84.55 and 84.95 (C3 and C4), 169.97 (C=O).
- (13) 14, dec. 204-206°C; $[\alpha]_D^{20}$ +30 (c=1.4; CHCl₃)

¹HNMR (400MHz; CDCl₃): δ 1.50 (q, 1H, H6a), 1 71 (s, 3H, CH₃CON), 2.24 (s, 3H, CH₃COS), 2.35 (dt, 1H, H6e, J_{6e-6a}=13.0 Hz), 3.40 (dd, 1H, H2, J₂₋₁=10 Hz, J₂₋₃=9.1 Hz), 3.50 (m, 2H, H4 and H5, J₄₋₃=J₄₋₅=9.0 Hz), 3.64 (t, 1H, H3), 3.75 (m, 1H, H1), 4.60-4.93 (m, 6H, <u>CH₂Ph)</u>, 4.95 (d, 1H, NH, J_{NH-1}=7.0 Hz), 7.25-7.37 (m, 15H, Ph); ¹³CNMR (100.6 MHz; CDCl₃): δ 23.40 (<u>CH₃CONH</u>), 30.72 (<u>CH₃COS</u>), 33.90 (C6), 43.43 (C5), 50.80 (C1), 81.27, 82.30 and 86.43 (C2, C3 and C4), 169.85 (HNC=O), 194.35 (SC=O).